Mara Goldstein
Stock Analyst at Mizuho
(4.16)
# 618
Out of 4,412 analysts
62
Total ratings
49.02%
Success rate
15.39%
Average return
Main Sectors:
Top Industries:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $15.55 | +170.10% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $19.98 | +150.25% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $21.06 | +113.68% | 1 | Dec 22, 2023 | |
| KURA Kura Oncology | Initiates: Buy | $26 | $19.65 | +32.32% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $51.68 | +48.99% | 4 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.89 | +270.37% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $3.80 | +110.53% | 3 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $3.25 | +269.23% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $11.64 | +157.73% | 4 | Sep 15, 2023 | |
| VSTM Verastem | Reiterates: Buy | $36 | $9.38 | +283.80% | 5 | Aug 29, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $6 | $1.32 | +354.55% | 3 | Aug 7, 2023 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Neutral | $3.5 | $1.45 | +141.38% | 4 | Jun 16, 2023 | |
| INAB IN8bio | Reiterates: Buy | $12 | $1.04 | +1,053.85% | 2 | Apr 24, 2023 | |
| IMRX Immuneering | Upgrades: Buy | $10 → $20 | $1.47 | +1,260.54% | 2 | Apr 19, 2023 | |
| MRK Merck & Co. | Reiterates: Buy | $130 | $131.20 | -0.91% | 2 | Apr 10, 2023 | |
| CTMX CytomX Therapeutics | Maintains: Neutral | $4 → $2 | $1.59 | +25.79% | 3 | Mar 28, 2023 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $18 → $12 | $4.00 | +200.00% | 2 | Mar 8, 2023 | |
| ADAP Adaptimmune Therapeutics | Upgrades: Buy | $9 | $1.08 | +737.21% | 2 | Nov 9, 2022 | |
| EFTR eFFECTOR Therapeutics | Initiates: Buy | $500 | $1.89 | +26,355.03% | 1 | Oct 4, 2021 | |
| ARRY Array Technologies | Initiates: Overweight | n/a | $12.40 | - | 3 | Jan 15, 2019 | |
| CYTK Cytokinetics | Initiates: Overweight | n/a | $65.34 | - | 2 | Sep 21, 2018 | |
| CLDX Celldex Therapeutics | Downgrades: Neutral | n/a | $36.30 | - | 2 | Apr 17, 2018 | |
| ADXS Ayala Pharmaceuticals | Maintains: Overweight | n/a | $0.56 | - | 1 | Mar 13, 2018 | |
| ARDX Ardelyx | Maintains: Overweight | n/a | $6.42 | - | 1 | Oct 12, 2017 |
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $15.55
Upside: +170.10%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $19.98
Upside: +150.25%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $21.06
Upside: +113.68%
Kura Oncology
Dec 22, 2023
Initiates: Buy
Price Target: $26
Current: $19.65
Upside: +32.32%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $51.68
Upside: +48.99%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.89
Upside: +270.37%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $3.80
Upside: +110.53%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $3.25
Upside: +269.23%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $11.64
Upside: +157.73%
Verastem
Aug 29, 2023
Reiterates: Buy
Price Target: $36
Current: $9.38
Upside: +283.80%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $1.32
Upside: +354.55%
Corvus Pharmaceuticals
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $1.45
Upside: +141.38%
IN8bio
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $1.04
Upside: +1,053.85%
Immuneering
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.47
Upside: +1,260.54%
Merck & Co.
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $131.20
Upside: -0.91%
CytomX Therapeutics
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.59
Upside: +25.79%
Autolus Therapeutics
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $4.00
Upside: +200.00%
Adaptimmune Therapeutics
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $1.08
Upside: +737.21%
eFFECTOR Therapeutics
Oct 4, 2021
Initiates: Buy
Price Target: $500
Current: $1.89
Upside: +26,355.03%
Array Technologies
Jan 15, 2019
Initiates: Overweight
Price Target: n/a
Current: $12.40
Upside: -
Cytokinetics
Sep 21, 2018
Initiates: Overweight
Price Target: n/a
Current: $65.34
Upside: -
Celldex Therapeutics
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $36.30
Upside: -
Ayala Pharmaceuticals
Mar 13, 2018
Maintains: Overweight
Price Target: n/a
Current: $0.56
Upside: -
Ardelyx
Oct 12, 2017
Maintains: Overweight
Price Target: n/a
Current: $6.42
Upside: -